Skip to content

Pipeline

We are advancing a robust pipeline of cell therapies programmed with multiple coordinated synthetic drug functions.
Product
Target Discovery & Validation
Candidate Selection
IND Enabling
Early Clinical
Late Clinical
Wholly Owned Programs
AB-3028
end of IND enabling phase
Prostate
FIH anticipated 1H'26
AB-7000
end of IND enabling phase
Undisclosed Indication

AB-3028

AB-3028 is intended for patients with metastatic castration-resistant prostate cancer. It uses a similar therapeutic approach to AB-1015 and AB-2100, and focuses on tumor targets found in a large proportion of advanced prostate cancer tumors. Our team has introduced additional enhancements aimed at improving cell performance in the suppressive tumor microenvironment. The goals are to increase tumor killing, to support longer persistence in the body, and to limit exhaustion after repeated encounters with cancer cells.

AB-7000

AB-7000 is in preclinical development. We will share information about the intended indication, target antigens, and therapeutic enhancements as the program advances.

AB-7000

AB-7000 is in preclinical development. We will share information about the intended indication, target antigens, and therapeutic enhancements as the program advances.

AB-2100

For more information on the Phase 1 study, please go to clinicaltrials.gov (NCT06245915). No further enrollment.

AB-1015

For more information on the Phase 1 study, please go to clinicaltrials.gov (NCT05617755). No further enrollment.

Bristol Myers Squibb

Bristol Myers Squibb Collaboration

In addition to our robust pipeline of wholly-owned programs, we have partnered with Bristol Myers Squibb in a multi-program discovery collaboration to advance next-generation T-cell therapies for solid tumors. This collaboration combines our programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development. We are currently discovering and building preclinical candidates against multiple targets, and Bristol Myers Squibb can obtain an exclusive worldwide license to develop and commercialize these candidates.